HK1250513A1 - 抗ox40抗體及其使用方法 - Google Patents
抗ox40抗體及其使用方法Info
- Publication number
- HK1250513A1 HK1250513A1 HK18109884.0A HK18109884A HK1250513A1 HK 1250513 A1 HK1250513 A1 HK 1250513A1 HK 18109884 A HK18109884 A HK 18109884A HK 1250513 A1 HK1250513 A1 HK 1250513A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562158515P | 2015-05-07 | 2015-05-07 | |
US201562161198P | 2015-05-13 | 2015-05-13 | |
US201562262373P | 2015-12-02 | 2015-12-02 | |
US201662323458P | 2016-04-15 | 2016-04-15 | |
PCT/US2016/031257 WO2016179517A1 (en) | 2015-05-07 | 2016-05-06 | Anti-ox40 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1250513A1 true HK1250513A1 (zh) | 2018-12-21 |
Family
ID=56015132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109884.0A HK1250513A1 (zh) | 2015-05-07 | 2018-07-31 | 抗ox40抗體及其使用方法 |
Country Status (18)
Country | Link |
---|---|
US (8) | US10259882B2 (zh) |
EP (1) | EP3292152A1 (zh) |
JP (3) | JP6867955B2 (zh) |
KR (1) | KR20180015650A (zh) |
CN (2) | CN115109158A (zh) |
AU (2) | AU2016256911B2 (zh) |
BR (1) | BR112017023849A2 (zh) |
CA (1) | CA2984794A1 (zh) |
EA (1) | EA201792451A1 (zh) |
HK (1) | HK1250513A1 (zh) |
IL (1) | IL255278A0 (zh) |
MA (1) | MA42043A (zh) |
MX (1) | MX2017014188A (zh) |
MY (1) | MY189692A (zh) |
PH (1) | PH12017502013A1 (zh) |
SG (1) | SG11201708804WA (zh) |
TW (2) | TWI716405B (zh) |
WO (1) | WO2016179517A1 (zh) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2609118T (pt) * | 2010-08-23 | 2017-03-22 | Univ Texas | Anticorpos anti-ox40 e métodos de utilização dos mesmos |
BR112015023862A2 (pt) | 2013-03-18 | 2017-10-24 | Biocerox Prod Bv | anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado |
KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
AU2016215175B2 (en) * | 2015-02-06 | 2021-09-16 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
MA42043A (fr) | 2015-05-07 | 2018-03-14 | Agenus Inc | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
CN114380908B (zh) | 2015-10-15 | 2023-03-17 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
CN116063542A (zh) | 2015-12-02 | 2023-05-05 | 阿吉纳斯公司 | 抗体和其使用方法 |
CA3006963A1 (en) * | 2015-12-03 | 2017-06-08 | Ludwig Institute For Cancer Research Ltd. | Anti-ox40 antibodies and methods of use thereof |
RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
TWI765885B (zh) * | 2016-04-21 | 2022-06-01 | 美商菲歐普提斯公司 | 利用黑色素校正之測定組織氧飽和度的方法和裝置 |
EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
AU2017373945A1 (en) | 2016-12-07 | 2019-06-20 | Agenus Inc. | Antibodies and methods of use thereof |
SG10201914126RA (en) * | 2016-12-15 | 2020-02-27 | Abbvie Biotherapeutics Inc | Anti-ox40 antibodies and their uses |
JP2020504105A (ja) | 2016-12-19 | 2020-02-06 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なtnfrアゴニストおよびその使用 |
CN108623686A (zh) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
BR112019021680A2 (pt) | 2017-04-20 | 2020-05-12 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? |
MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
KR20200087143A (ko) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | 핫스팟을 이용한 신생항원 동정 |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
CN108218990B (zh) * | 2017-12-29 | 2021-03-02 | 南京优迈生物科技有限公司 | 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用 |
AU2019264712A1 (en) | 2018-05-11 | 2021-01-07 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against OX40, method for preparing same, and use thereof |
US20220111065A1 (en) | 2018-05-23 | 2022-04-14 | Adc Therapeutics Sa | Molecular adjuvant |
CR20200653A (es) | 2018-07-03 | 2021-02-11 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y métodos de uso |
WO2020014583A1 (en) | 2018-07-13 | 2020-01-16 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor |
AU2019347934A1 (en) | 2018-09-26 | 2021-04-08 | Jiangsu Hengrui Medicine Co., Ltd. | An anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |
JP7453219B2 (ja) | 2018-10-11 | 2024-03-19 | インヒブリックス, インコーポレイテッド | Pd-1単一ドメイン抗体およびその治療用組成物 |
AU2019381526B2 (en) * | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
WO2020132857A1 (zh) * | 2018-12-25 | 2020-07-02 | 杭州翰思生物医药有限公司 | 抗ox40的单克隆抗体及其应用 |
US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
TWI762925B (zh) | 2019-05-21 | 2022-05-01 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
WO2020259667A1 (zh) * | 2019-06-28 | 2020-12-30 | 江苏恒瑞医药股份有限公司 | Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 |
EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的t細胞の製造方法 |
CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン, インコーポレイテッド | 抗cd47及び抗cd20による血液癌の治療 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
PE20221506A1 (es) | 2019-12-17 | 2022-10-04 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
CR20220547A (es) | 2020-05-01 | 2022-12-15 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 |
WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
CN111704671B (zh) * | 2020-08-19 | 2020-11-24 | 广东赛尔生物科技有限公司 | Ox40抗体及其在治疗癌症中的应用 |
CN112442121A (zh) * | 2020-08-20 | 2021-03-05 | 山东兴瑞生物科技有限公司 | Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用 |
CN114106174A (zh) * | 2020-08-27 | 2022-03-01 | 苏州景涞医疗科技有限公司 | 低毒性抗ox40抗体、其药物组合物及应用 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
AU2021377614A1 (en) | 2020-11-11 | 2023-06-22 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (251)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US886573A (en) | 1907-05-04 | 1908-05-05 | Albanus S Aiman | Weather-strip. |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
US5759546A (en) | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6027947A (en) | 1996-08-20 | 2000-02-22 | Ramtron International Corporation | Partially or completely encapsulated top electrode of a ferroelectric capacitor |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CZ294425B6 (cs) | 1997-04-14 | 2005-01-12 | Micromet Ag | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
CA2321161C (en) | 1998-02-24 | 2011-12-20 | Andrew D. Weinberg | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
US20030035790A1 (en) | 1999-01-15 | 2003-02-20 | Shu-Hsia Chen | Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
AU2002213001A1 (en) | 2000-10-02 | 2002-04-15 | The Regents Of The University Of California | Methods and compositions for modulating T cell activation and uses thereof |
CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP1333032A4 (en) | 2000-10-06 | 2005-03-16 | Kyowa Hakko Kogyo Kk | METHOD FOR PURIFYING ANTIBODIES |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20150329617A1 (en) | 2001-03-14 | 2015-11-19 | Dynal Biotech Asa | Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
US20040009174A1 (en) | 2001-12-18 | 2004-01-15 | Arndt Gregory Martin | Method of treating asthma |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
KR101196023B1 (ko) | 2002-03-19 | 2012-10-30 | 스티칭 디엔스트 랜드보위쿤디그 온데조에크 | 식물에서 글리칸 프로세싱의 최적화 |
MXPA04009394A (es) | 2002-03-26 | 2005-01-25 | Inmunex Corp | Metodos para utilizar ligando flt3 en procedimientos de inmunizacion. |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
US20030223989A1 (en) | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
EP1551449B1 (en) | 2002-07-12 | 2010-10-06 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
JP2006512942A (ja) | 2002-10-25 | 2006-04-20 | ユニバーシティー オブ コネティカット ヘルス センター | 制御細胞溶解による癌の免疫療法のための装置と方法 |
DE10261223A1 (de) | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
JP2006512391A (ja) | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | 組み合わせ免疫賦活薬 |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
AU2004205802B2 (en) | 2003-01-22 | 2009-11-05 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function |
GB0303319D0 (en) | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
GB0303663D0 (en) | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US20070010450A1 (en) | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
WO2005049085A1 (en) | 2003-11-18 | 2005-06-02 | Valeocyte Therapies Llc | Use of soluble complexes to facilitate cell activation |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
ES2402298T3 (es) | 2004-01-19 | 2013-04-30 | Novartis Ag | Derivados de indolilmaleimida como inhibidores del tratamiento de rechazo del injerto o enfermedades autoinmunes |
US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
US8124085B2 (en) | 2004-05-05 | 2012-02-28 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
CN100509848C (zh) * | 2005-04-07 | 2009-07-08 | 苏州大学 | 抗人ox40l单克隆抗体制备及应用 |
EP2650020B1 (en) | 2005-05-06 | 2016-08-24 | Providence Health & Services - Oregon | Trimeric OX40-immunoglobulin fusion protein and methods of use |
CA2605781A1 (en) | 2005-05-09 | 2007-04-12 | Glycart Biotechnology Ag | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
GB0512225D0 (en) | 2005-06-16 | 2005-07-27 | Univ Sheffield | Immunoglobulin molecules |
JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
JP5281399B2 (ja) | 2005-07-29 | 2013-09-04 | プロビデンス ヘルス システム | 小胞(dribble)中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法 |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
AR057253A1 (es) | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
WO2007084559A2 (en) | 2006-01-13 | 2007-07-26 | Board Of Regents, The University Of Texas System | Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor |
US20110008368A1 (en) | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
AU2007205935B2 (en) | 2006-01-17 | 2013-07-11 | Synthon Biopharmaceuticals B.V. | Compositions and methods for humanization and optimization of N-glycans in plants |
US20100015143A1 (en) | 2006-03-22 | 2010-01-21 | Tracy Hussell | Compositions and Methods Relating to Modulation of Immune System Components |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
WO2007130555A2 (en) | 2006-05-02 | 2007-11-15 | Providence Health System | Augmentation of immune response to cancer vaccine |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
US10106619B2 (en) | 2006-10-04 | 2018-10-23 | La Jolla Institute For Allergy And Immunology | Virus vaccination and treatment methods with OX40 agonist compositions |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
RU2009135824A (ru) | 2007-02-27 | 2011-04-10 | Дженентек, Инк. (Us) | Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний |
EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
WO2009030237A2 (en) | 2007-09-07 | 2009-03-12 | Symphogen A/S | Methods for recombinant manufacturing of anti-rsv antibodies |
CA2699394C (en) | 2007-09-17 | 2020-03-24 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
EP3239178A1 (en) | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
CN102272158B (zh) | 2008-11-12 | 2014-05-07 | 乔治·K·刘易斯 | 源自记忆b细胞的人单克隆抗体的快速表达克隆 |
JP5782385B2 (ja) | 2009-02-17 | 2015-09-24 | ユーシービー ファーマ ソシエテ アノニム | ヒトox40に対する特異性を有する抗体分子 |
JPWO2010110346A1 (ja) | 2009-03-24 | 2012-10-04 | 独立行政法人理化学研究所 | 白血病幹細胞マーカー |
SG10201501784YA (en) | 2009-12-07 | 2015-05-28 | Univ Leland Stanford Junior | Methods for enhancing anti-tumor antibody therapy |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
WO2011097527A2 (en) | 2010-02-04 | 2011-08-11 | Xencor, Inc. | Immunoprotection of therapeutic moieties using enhanced fc regions |
DK2542590T4 (da) | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
GB201006096D0 (en) | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
US20110256184A1 (en) | 2010-04-14 | 2011-10-20 | Battelle Memorial Institute | Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release |
EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
WO2012012518A2 (en) | 2010-07-20 | 2012-01-26 | University Of Miami | Inhibition of nonsense mediated decay pathways |
PT2609118T (pt) * | 2010-08-23 | 2017-03-22 | Univ Texas | Anticorpos anti-ox40 e métodos de utilização dos mesmos |
US20130295091A1 (en) | 2011-01-10 | 2013-11-07 | University Of Zurich | Combination therapy including tumor associated antigen binding antibodies |
MX354359B (es) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
CN105601741A (zh) | 2011-04-15 | 2016-05-25 | 卡姆普根有限公司 | 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途 |
JP2014524891A (ja) | 2011-06-03 | 2014-09-25 | シーティー アトランティック リミテッド | Magea3結合抗体 |
CN103796680A (zh) | 2011-06-21 | 2014-05-14 | 约翰霍普金斯大学 | 用于增强针对赘生物的基于免疫的治疗的聚焦放射 |
AU2012282116B2 (en) | 2011-07-11 | 2016-07-07 | Ichnos Sciences SA | Antibodies that bind to OX40 and their uses |
EP2748199B1 (en) * | 2011-08-23 | 2019-08-28 | Board of Regents, The University of Texas System | Anti-ox40 antibodies and methods of using the same |
GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
WO2013049307A2 (en) | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
SG11201401649VA (en) | 2011-11-11 | 2014-07-30 | Ucb Pharma Sa | Albumin binding antibodies and binding fragments thereof |
EP2785683B1 (en) | 2011-11-30 | 2020-02-05 | Ludwig Institute for Cancer Research Ltd. | Inkt cell modulators and methods of using the same |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
US9718893B2 (en) * | 2011-12-19 | 2017-08-01 | Synimmune Gmbh | Bispecific antibody molecule |
KR102081567B1 (ko) | 2012-01-25 | 2020-02-26 | 디엔에이트릭스, 인코포레이티드 | 바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법 |
CN104185681A (zh) | 2012-02-01 | 2014-12-03 | 卡姆普根有限公司 | C1orf32抗体及其用于治疗癌症的用途 |
US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
LT2814844T (lt) | 2012-02-15 | 2017-10-25 | Novo Nordisk A/S | Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1) |
JP2015509717A (ja) | 2012-02-22 | 2015-04-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗腫瘍活性およびcar存続性を強化するためのicosベースのcarの使用 |
AU2013222185B2 (en) | 2012-02-23 | 2018-07-26 | Sloan-Kettering Institute For Cancer Research | Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment |
US20150157710A1 (en) | 2012-03-02 | 2015-06-11 | Providence Health & Services-Oregon D/B/A Providence Portland Medical Center | Dual ox40 agonist/il-2 cancer therapy methods |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
NZ622452A (en) | 2012-06-21 | 2017-10-27 | Compugen Ltd | Lsr antibodies, and uses thereof for treatment of cancer |
CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
JP2015523412A (ja) | 2012-07-30 | 2015-08-13 | ワウ ヒン イェウング,アレックス | 腫瘍細胞、GM‐CSFのトランスジェニック発現を伴う腫瘍溶解性ウイルスベクター、および免疫チェックポイントモジュレーターなどの成分の少なくとも2種または全3種の同時投与により作られる生のinvivo腫瘍特異的がんワクチンシステム |
EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
US10533054B2 (en) | 2013-01-31 | 2020-01-14 | Thomas Jefferson University | Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system |
WO2014128245A1 (en) | 2013-02-21 | 2014-08-28 | CORAL, Sandra | Dna hypomethylating agents for cancer therapy |
BR112015023862A2 (pt) | 2013-03-18 | 2017-10-24 | Biocerox Prod Bv | anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado |
AU2014290186A1 (en) | 2013-07-15 | 2016-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of CD38 agonists |
US10966998B2 (en) | 2013-09-05 | 2021-04-06 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
US9493563B2 (en) | 2013-11-04 | 2016-11-15 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
EP3065772A4 (en) | 2013-11-05 | 2017-09-13 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
CN114317461A (zh) | 2013-11-22 | 2022-04-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
EP3083687A2 (en) | 2013-12-17 | 2016-10-26 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
MX369173B (es) | 2013-12-24 | 2019-10-30 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista. |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
NZ747418A (en) | 2014-03-12 | 2023-05-26 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
CR20160500A (es) | 2014-03-31 | 2016-12-14 | Genentech Inc | Anticuerpos anti-ox40 y métodos de uso |
WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
KR20170002410A (ko) | 2014-04-03 | 2017-01-06 | 오거스타 유니버시티 리서치 인스티튜트, 인크. | 종양 유도 면역 반응의 효능을 향상시키는 방법 |
WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
EP2939690A1 (en) | 2014-04-29 | 2015-11-04 | Medizinische Hochschule Hannover | Vaccine |
BR112016026299A2 (pt) | 2014-05-13 | 2018-02-20 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão |
SG10201810507WA (en) | 2014-06-06 | 2018-12-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2015197874A2 (en) | 2014-06-27 | 2015-12-30 | Apogenix Gmbh | Combination of cd95/cd95l inhibition and cancer immunotherapy |
US10449227B2 (en) | 2014-06-27 | 2019-10-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
US20180064765A1 (en) | 2014-07-18 | 2018-03-08 | Advaxis, Inc. | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
WO2016025645A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
UA122395C2 (uk) | 2014-08-19 | 2020-11-10 | Мерк Шарп Енд Доум Корп. | Антитіло проти tigit |
EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
CA2963281A1 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Combination therapies |
CA2964155A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
CN107106590B (zh) | 2014-10-24 | 2022-10-18 | 阿斯利康(瑞典)有限公司 | 组合 |
EP3209382B1 (en) | 2014-10-24 | 2020-11-25 | Calidi Biotherapeutics, Inc. | Combination immunotherapy approach for treatment of cancer |
EP3212228A2 (en) | 2014-10-27 | 2017-09-06 | Ruprecht-Karls-Universität Heidelberg | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer |
JP7305300B2 (ja) | 2014-11-05 | 2023-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 併用免疫療法 |
WO2016073282A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
CN106999594B (zh) | 2014-11-11 | 2020-08-18 | 免疫医疗有限公司 | 用于治疗瘤形成的治疗组合 |
WO2016090347A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
CA3224830A1 (en) | 2015-01-08 | 2016-07-14 | Biontech Ag | Agonistic tnf receptor binding agents |
JP2018512397A (ja) | 2015-03-11 | 2018-05-17 | プロビデンス ヘルス アンド サービシーズ−オレゴン | 癌治療の有効性を高めるための組成物及び方法 |
BR112017020491A2 (pt) | 2015-03-25 | 2018-07-17 | The Regents Of The University Of Michigan | composições e métodos para distribuição de agentes de biomacromolécula. |
WO2016168361A1 (en) | 2015-04-14 | 2016-10-20 | Polynoma, Llc | Polyvalent vaccines and combination therapy for the treatment of melanoma |
MA42043A (fr) * | 2015-05-07 | 2018-03-14 | Agenus Inc | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci |
AU2016263198C1 (en) | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
PE20180926A1 (es) | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
RU2729379C1 (ru) | 2015-10-01 | 2020-08-06 | Потенза Терапевтикс, Инк. | Анти-tigit антигенсвязывающие белки и способы их применения |
CN116063542A (zh) | 2015-12-02 | 2023-05-05 | 阿吉纳斯公司 | 抗体和其使用方法 |
WO2017096281A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
CA3006963A1 (en) | 2015-12-03 | 2017-06-08 | Ludwig Institute For Cancer Research Ltd. | Anti-ox40 antibodies and methods of use thereof |
US20190175748A1 (en) | 2016-03-16 | 2019-06-13 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
-
2016
- 2016-05-06 MA MA042043A patent/MA42043A/fr unknown
- 2016-05-06 MY MYPI2017001627A patent/MY189692A/en unknown
- 2016-05-06 EA EA201792451A patent/EA201792451A1/ru unknown
- 2016-05-06 KR KR1020177035013A patent/KR20180015650A/ko not_active Application Discontinuation
- 2016-05-06 CN CN202210581278.7A patent/CN115109158A/zh active Pending
- 2016-05-06 BR BR112017023849A patent/BR112017023849A2/pt active Search and Examination
- 2016-05-06 WO PCT/US2016/031257 patent/WO2016179517A1/en active Application Filing
- 2016-05-06 AU AU2016256911A patent/AU2016256911B2/en active Active
- 2016-05-06 MX MX2017014188A patent/MX2017014188A/es unknown
- 2016-05-06 JP JP2017557938A patent/JP6867955B2/ja active Active
- 2016-05-06 US US15/148,720 patent/US10259882B2/en active Active
- 2016-05-06 TW TW105114161A patent/TWI716405B/zh active
- 2016-05-06 CN CN201680039426.5A patent/CN108137686B/zh active Active
- 2016-05-06 CA CA2984794A patent/CA2984794A1/en active Pending
- 2016-05-06 SG SG11201708804WA patent/SG11201708804WA/en unknown
- 2016-05-06 TW TW110100363A patent/TWI820377B/zh active
- 2016-05-06 EP EP16723616.5A patent/EP3292152A1/en active Pending
-
2017
- 2017-10-26 IL IL255278A patent/IL255278A0/en unknown
- 2017-11-06 PH PH12017502013A patent/PH12017502013A1/en unknown
-
2018
- 2018-07-31 HK HK18109884.0A patent/HK1250513A1/zh unknown
-
2019
- 2019-02-25 US US16/284,811 patent/US11136404B2/en active Active
- 2019-04-15 US US16/384,116 patent/US10626181B2/en active Active
-
2020
- 2020-02-07 US US16/784,469 patent/US11332536B2/en active Active
- 2020-03-03 US US16/808,074 patent/US11472883B2/en active Active
-
2021
- 2021-04-09 JP JP2021066377A patent/JP7404303B2/ja active Active
- 2021-09-01 US US17/446,706 patent/US20220098316A1/en not_active Abandoned
-
2022
- 2022-03-15 AU AU2022201791A patent/AU2022201791A1/en active Pending
- 2022-09-08 US US17/930,555 patent/US20230108348A1/en active Pending
- 2022-09-08 US US17/930,542 patent/US20230167186A1/en active Pending
-
2023
- 2023-07-27 JP JP2023122389A patent/JP2023156367A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250513A1 (zh) | 抗ox40抗體及其使用方法 | |
HK1249445A1 (zh) | 抗分揀蛋白抗體和其使用方法 | |
HK1252698A1 (zh) | 抗siglec-9抗體及其使用方法 | |
IL259495A (en) | Antibodies and methods for using them | |
ZA201606630B (en) | Anti-ox40 antibodies and methods of use | |
HK1252696A1 (zh) | 抗siglec-7抗體及其使用方法 | |
EP3383914A4 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
HK1259251A1 (zh) | 人源化抗c1s抗體及其使用方法 | |
IL270793A (en) | Anti-HTRA1 antibodies and methods of using them |